Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis

Renal Failure

Volumn 29, Issue 7, 2007, Pages 927-930

  Tahmaz, M ^a   Kumbasar, B ^a   Ergen, K ^a   Ure, U ^a   Karatemiz, G ^a   Kazancioglu, R ^a,b  

^a Haseki Training and Research Hospital   (Turkey)

^b HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acute renal failure; Fenofibrate; Rhabdomyolysis

Indexed keywords

AMLODIPINE; BICARBONATE; CANDESARTAN HEXETIL; CREATININE; DIURETIC AGENT; FENOFIBRATE; HYDROCHLOROTHIAZIDE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CASE REPORT; CONVALESCENCE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HISTORY OF MEDICINE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYDRATION; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; MONOTHERAPY; MYALGIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHABDOMYOLYSIS; URINALYSIS; URINE COLOR; WEAKNESS;

ADULT; ANTILIPEMIC AGENTS; CREATINE KINASE; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; PROCETOFEN; RHABDOMYOLYSIS;

EID: 36249007039     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701573640     Document Type: Article

References (20)

1. Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol. 2000;11:1553-1561.
2. Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med. 1988;148:1553-1557.
3. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
4. Knoop RH. Drug treatment of lipid disorders. N Eng J Med. 1999;341:498-511.
5. Adkins JC, Faulds D. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia. Drugs. 1997;54:615-633.
6. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 2002;128:159-168.
7. Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 1996;19:311-326.
8. Thomas MA, Ibels LS. Rhabdomyolysis and acute renal failure. Aust NZJ Med. 1985;15:623-630.
9. Dovignon J. Fibrates: A review of important issues and recent findings. Can J Cardiol. 1994;10(S):61B-71B.
10. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmocokinet. 1998;14:156-162.
11. Graham DJ, Staff JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-2590.
12. Broeders N, Knoop C, Antoine M, Abramowicz D. Fibrate induced-renal dysfunction: Is gemfibrozil the only nonnephrotic agent? Transplantation. 1999;67S:S170.
13. Shepherd J. Fibrates and statins in the treatment of hyperlipidemia: An appraisal of their efficacy and safety. Eur Heart J. 1995;16:5-13.
14. Curry SC, Chong D, Connor D. Drug and toxin-induced rhabdomyolysis. Ann Emerg Med. 1989;18:1068-1084.
15. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine. 1982;61:141-153.
16. Atef MR, Nadjatfi I, Boroumand B, Rastegar A. Acute renal failure in earthquake victims in Iran: Epidemiology and management. Q J Med. 1994;87:35-40.
17. Barker JB, Goodenough RR, Falko MJ. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care. 2003;26:2482-2483.
18. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-122.
19. Gorriz JL, Sancho A, Lopez-Martin JM, et al. Rhabdomyolysis and acute renal failure associated with gemfibrozil monotherapy. Nephron. 1996;74:437-438.
20. Clouatre Y, Leblanc M, Ouimet D, Pichette V. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant. 1999;14:1047-1048.